Lupus Drug Trials Are Focusing On Clinical Response, Not Organ Endpoints
Executive Summary
Trials of the latest drug candidates for systemic lupus erythematosus are focusing on clinical response claims rather than taking the organ-specific approach used for prior investigational lupus agents